Cost-effectiveness analysis of interferon α-2b with ribavirin for chronic hepatitis C infection

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hepatitis C infection is often referred to as the 'silent epidemic' because so many persons are unaware they are infected with the virus. Interferon α (IFN) has been the mainstay treatment for hepatitis C, but IFN monotherapy generally does not result in sustained normalization of serum alanine aminotransferase. Recently, combination therapy with IFN plus ribavirin has been shown to increase therapeutic response, but at a substantial increase in drug acquisition costs. This article provides a critique of a recently published economic analysis comparing IFN and ribavirin combination therapy with IFN monotherapy.

Original languageEnglish (US)
Pages (from-to)681-689
Number of pages9
JournalFormulary
Volume35
Issue number8
StatePublished - Aug 2000

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Cost-Benefit Analysis
Infection
Hepatitis C
Drug Costs
Alanine Transaminase
Therapeutics
Economics
Viruses
Serum

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{95d4398ffbac4c1498213edef9164a91,
title = "Cost-effectiveness analysis of interferon α-2b with ribavirin for chronic hepatitis C infection",
abstract = "Hepatitis C infection is often referred to as the 'silent epidemic' because so many persons are unaware they are infected with the virus. Interferon α (IFN) has been the mainstay treatment for hepatitis C, but IFN monotherapy generally does not result in sustained normalization of serum alanine aminotransferase. Recently, combination therapy with IFN plus ribavirin has been shown to increase therapeutic response, but at a substantial increase in drug acquisition costs. This article provides a critique of a recently published economic analysis comparing IFN and ribavirin combination therapy with IFN monotherapy.",
author = "Malone, {Daniel C.} and Armstrong, {Edward P} and Grizzle, {Amy J.}",
year = "2000",
month = "8",
language = "English (US)",
volume = "35",
pages = "681--689",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "8",

}

TY - JOUR

T1 - Cost-effectiveness analysis of interferon α-2b with ribavirin for chronic hepatitis C infection

AU - Malone, Daniel C.

AU - Armstrong, Edward P

AU - Grizzle, Amy J.

PY - 2000/8

Y1 - 2000/8

N2 - Hepatitis C infection is often referred to as the 'silent epidemic' because so many persons are unaware they are infected with the virus. Interferon α (IFN) has been the mainstay treatment for hepatitis C, but IFN monotherapy generally does not result in sustained normalization of serum alanine aminotransferase. Recently, combination therapy with IFN plus ribavirin has been shown to increase therapeutic response, but at a substantial increase in drug acquisition costs. This article provides a critique of a recently published economic analysis comparing IFN and ribavirin combination therapy with IFN monotherapy.

AB - Hepatitis C infection is often referred to as the 'silent epidemic' because so many persons are unaware they are infected with the virus. Interferon α (IFN) has been the mainstay treatment for hepatitis C, but IFN monotherapy generally does not result in sustained normalization of serum alanine aminotransferase. Recently, combination therapy with IFN plus ribavirin has been shown to increase therapeutic response, but at a substantial increase in drug acquisition costs. This article provides a critique of a recently published economic analysis comparing IFN and ribavirin combination therapy with IFN monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0033903538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033903538&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033903538

VL - 35

SP - 681

EP - 689

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 8

ER -